Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Labeling errors & mix-ups

Wrong label, wrong strength, mixed-up products, or packaging errors. One of the most dangerous causes - you can end up taking the wrong drug or the wrong dose.

1,411 FDA drug recalls with this cause, newest first.

This is exactly what it sounds like: the wrong label on the right product, the wrong strength printed on the bottle, a missing or illegible lot number and expiry date, or two products mixed up during packaging. It is dangerous precisely because the pill or liquid itself may be fine, yet the patient has no way of knowing what they are actually taking. A high share of the Class I recalls in this group are mix-ups where a stronger product ended up in a weaker product's packaging.

Class I · High risk

Acetaminophen Extra Strength Tablets

Labeling: Label Mix-Up: Some bottles of Acetaminophen Extra Strength 500 mg tablets were incorrectly labeled with the drug facts label for Aspirin 81 mg tablets.

Terminated Labeling / mix-up A-S Medication Solutions LLC D-0631-2024
Class III · Low risk

Complete 30C/200C Homeopathic Kit

Labeling: Label Mix-up: Some bottles of Ferrum Phosphoricum 200C were incorrectly labeled as Ferrum Metallicum 200C.

Terminated Labeling / mix-up Washington Homeopathic Products, Inc. D-0618-2024
Class II · Moderate risk

Phenazopyridine HCl

Product Mix Up. A bottle labeled as Phenazopyridine HCl tablets USP 100 mg contained Phenobarbital tablets 16.2 mg.

Terminated Labeling / mix-up RemedyRepack Inc. D-0549-2024
Class II · Moderate risk

Petroleum Jelly

Labeling: Label Mix up; product labeled as pure white petroleum jelly actually contains petroleum jelly with Lavendar and Chamomile

Terminated Labeling / mix-up Consumer Product Partners, LLC D-0560-2024
Class III · Low risk

Tivicay PD

Labeling: Incorrect Lot and/or Expiration Date: The carton has incorrect expiration of 2026-MAY*, whereas the correct expiration date, which is on the tablet bottle label, is 2025-APR.

Terminated Labeling / mix-up GlaxoSmithKline LLC NDC 49702-255-37 D-0544-2024
Class III · Low risk

Cephalexin for Oral Suspension

Labeling: Not Elsewhere Classified: Back Label states 'Each contains: cephalexin monohydrate, USP equivalent to 5g' instead of Each Bottle contains: cephalexin monohydrate, USP equivalent to 10g'

Ongoing Labeling / mix-up Bryant Ranch Prepack, Inc. NDC 63629-9207-1 D-0540-2024
Class III · Low risk

Cephalexin for Oral Suspension

Labeling: Not Elsewhere Classified: Back Label states Each contains: cephalexin monohydrate, USP equivalent to 5g' on the back label instead of Each Bottle contains: cephalexin monohydrate, USP equivalent to 5g'

Ongoing Labeling / mix-up Bryant Ranch Prepack, Inc. NDC 63629-9206-1 D-0539-2024
Class III · Low risk

Cephalexin for Oral Suspension

Labeling: Not Elsewhere Classified: Back Label states 'Each contains: cephalexin monohydrate, USP equivalent to 5g' instead of Each Bottle contains: cephalexin monohydrate, USP equivalent to 10g'

Ongoing Labeling / mix-up Bryant Ranch Prepack, Inc. NDC 63629-8858-1 D-0538-2024
Class III · Low risk

Cephalexin for Oral Suspension

Labeling: Not Elsewhere Classified: Back label states Each contains: cephalexin monohydrate, USP equivalent to 2.5g' instead of Each Bottle contains: cephalexin monohydrate, USP equivalent to 5g

Ongoing Labeling / mix-up Bryant Ranch Prepack, Inc. NDC 63629-9205-1 D-0537-2024
Class III · Low risk

Cephalexin for Oral Suspension

Labeling: Not Elsewhere Classified: Front label states 100 Tablets instead of 100 ml and on the back label 'Each Tablet contains' instead of 'Each Bottle contains' No total dose per bottle listed should be 2.5 g'

Ongoing Labeling / mix-up Bryant Ranch Prepack, Inc. NDC 63629-9204-1 D-0536-2024
Class III · Low risk

Cyclophosphamide for Injection

Labeling: Incorrect or missing Package Insert: There is an error on the Package Insert (PI), section 2.3, Preparation, Handling, and Administration. The concentration of the reconstituted product is listed as '20 mg per vial.' This information should read: '20 mg per mL'.

Terminated Labeling / mix-up X-Gen Pharmaceuticals Inc. NDC 39822-0255-01 D-0434-2024
Class III · Low risk

Cyclophosphamide for Injection

Labeling: Incorrect or missing Package Insert: There is an error on the Package Insert (PI), section 2.3, Preparation, Handling, and Administration. The concentration of the reconstituted product is listed as '20 mg per vial.' This information should read: '20 mg per mL'.

Terminated Labeling / mix-up X-Gen Pharmaceuticals Inc. NDC 39822-0250-01 D-0433-2024
Class II · Moderate risk

Bicillin L-A

cGMP Deviations: Products were stored outside the drug label specifications.

Terminated Labeling / mix-up Mckesson Medical-Surgical Inc. Corporate Office NDC 60793-0701-10 D-0373-2024
Class II · Moderate risk

Rocuronium Bromide Injection

cGMP Deviations: Products were stored outside the drug label specifications.

Terminated Labeling / mix-up Mckesson Medical-Surgical Inc. Corporate Office NDC 55150-226-10 D-0371-2024
Class II · Moderate risk

Norepinephrine Bitartrate in 5% Dextrose Injection

Incorrect product concentration on the overwrap label: The overwrap label incorrectly identified the product strength as 4 mg / 250 mL; however, the primary bag label correctly identified the product strength as 8 mg / 250 mL.

Ongoing Labeling / mix-up Baxter Healthcare Corporation D-0336-2024
Class II · Moderate risk

Adrenalin (epinephrine)

Labeling: Incorrect or Missing Lot and/or Exp Date. The expiration date listed on the Repack Pouch Label is incorrect.

Completed Labeling / mix-up Henry Schein Inc. and Glove Club HSI Gloves Inc. NDC 42023-159-25 D-0342-2024
Class II · Moderate risk

Medline Remedy Clinical TREAT Antifungal Cream

Labeling: Not Elsewhere Classified; Product labeling contains the claim of 'Paraben Free' while the product does in fact contain parabens as part of the formulation/ ingredient list.

Ongoing Labeling / mix-up MEDLINE INDUSTRIES, LP - Northfield D-0315-2024